Wayne’s Egalet got some good news last week from the Food and Drug Administration after it approved the pharmaceutical company’s abuse-resistant opioid, Arymo, writes Dan McQuade for Philadelphia magazine.

Founded more than two decades ago in Denmark, the company relocated to suburban Philadelphia thanks to its current CEO, Robert Radie, who advocated for the move.

“One of the attractive aspects of this area is access to talent,” Radie said.

Add to that the presence of the local advocacy group Pennsylvania Bio, and the area seemed ripe for Egalet.

According to Radie, the company was ready for the FDA’s approval, and is hoping to have Arymo on the market early this year. It deters abuse of the opioid by using a proprietary technology called Guardian.

“Our technology confers physical and chemical barriers to the typical way that people would try to manipulate a product at the first step toward abuse and misuse,” he said.

Read the entire interview in Philadelphia magazine here, and check out previous VISTA Today coverage of Egalet here.